Syngene International Increases Global Reach with $50 Million US Investment and Increased Bioreactor Capability

Syngene International Limited has made major strategic investments. The company is making around $50 million worth of investment in its first US facility, which represents a big move into the US market. This investment will further boost Syngene's strength in supporting global pharmaceutical and biotechnology customers.

 

In addition, Syngene has expanded its bioreactor capacity to 50,000 liters at a new facility, enhancing its manufacturing strength. Syngene has also acquired its first USA biologics facility, further cementing its foothold in the international biologics market.

 

These events come in the wake of recent regulatory audits, during which Syngene's Bengaluru site garnered five USFDA observations. This notwithstanding, the company is determined to rectify these issues and continues to drive innovation and global growth.

 

Source: Based on Syngene International's Press Release report and JM Financial Services report

Source: Based on Syngene International's Press Release report and JM Financial Services report